Clinical Trial Update: Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 18F-PSMA PET/CT imaging for PSMA-positive tumors, with recruitment ongoing in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA PET/CT imaging agent (18F-PSMA)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Malignancy | Phase 2 | Status: RECRUITING